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Building on data published by MC Vos 
and colleagues in 1992 on im- 
ipenem/cilastatin and CAVHD [1] we in­
vestigated imipenem/cilastatin in 16 pa­
tients with (n = 10, group 1) and without 
in = 6, group 2) renal insufficiency; both 
groups received continuous, volume-con- 
stant hémofiltration (CVHF). The indica­
tions for hémofiltration were oliguric re­
nal dysfunction and increases in urea and 
creatinine of 8 mmol/day and 
50 iiimol/day, respectively. CVHF was per­
formed as a postdilution technique with a 
polysulfone high-flux filter and an blood 
pump. The blood flow ranged from 100 
to 200 ml/min and was adjusted to 
Qjt = 20-30ml/min. The filter was dis­
charged when transmembrane pressure 
reached 200 mmHg of when the volumes 
of filtrate dropped to 50% of the initial 
filtration rate. Anticoagulation was main­
tained with up to 1000IU heparin/h to 
keep PTT at about 40 s. Arterial blood 
and ultrafiltrate samples were collected 
10, 20 and 30 min and every hour from 1 
to 12 h after the beginning of imipenem/ 
cilastatin infusion. Pharmacokinetics were 
calculated under the condition of steady- 
state application. Curve approximation 
according to serum and cumulative 
ultrafiltrate levels was calculated by a 
least-square iteration process with the 
TOPFIT pharmacokinetic program.
A predictive algorithm for drug dosage 
during HF was developed to obtain a suf­
ficient dosage without measuring blood 
levels. It was based on Dettli’s equation 
for renal insufficiency [2]: D = Dn 
(Qx + QFxS/C ln), where Qx = individual 
extracorporeal elimination fraction;
QF = filtration flow (ml/min); S = drug 
sieving ( = 1-protein binding), and Cln of 
imipenem was taken from our control 
group. For imipenem, we presume only a 
low influence of Qx on dosage because 
the normal Qx (= Q0) was 0.3.
Continuous, volume-constant 
hémofiltration is becoming recognized as 
the best treatment for ARF. This method 
replaced arteriovenous hémofiltration and 
dialysis because of its fewer side effects: 
CAVH depends on a sufficient blood 
pressure for Q F, and dialysis sometimes 
affects patients' circulation.
Peak levels of imipenem were lower 
than those reported in the literature [3, 4]. 
Imipenem has a marked metabolic degra­
dation, and therefore half-lives were only 
doubled compared to normals (group 1: 
2.21 ±0.59 h, group 2: 1.38±0.41 h, nor­
mals: 1.0 h. This is the reason for the low 
calculated initial concentration and the 
lower area under the curve (AUC). The 
extrapolated initial concentration C0 has 
a mean of 30.7 mg/1, which, however, is 
still comparable to results of other au­
thors [1, 3]. Sieving coefficient was calcu­
lated from the area under the curve of se­
rum and ultrafiltrate because this method 
resulted in smaller standard deviations 
with respect to predictive values than 
from single data. Qx of group 1 was al­
ways greater than the normal elimination. 
The dosage reduction factor was 0.4. Dos­
age corrections following CVHF are small 
compared to non-renal elimination. This 
would imply that the CVHF correction is 
comparable to untreated end-stage renal 
disease. Cilastatin has no antibiotic effect 
and accumulates during renal dysfunction. 
In patients with no kidney function, 
cislatin is not indicated. The results con­
firmed the prediction for ARF patients: 
the dose of imipenem/cilastatin has to be 
reduced from 4g/day to 1.5~3.0g/day in 
patients with ARF during CVHF.
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Sir: We would like to report on a primary 
laryngospasm in a patient with Parkin­
son’s disease and its treatment with CPAP 
(continuous positive airway pressure) via 
minitracheostomy,
A 60-year-old man with about a 
10-year history of Parkinson’s disease 
treated with Sinemet (carbidopa and 
levodopa) was admitted to the hospital 
with a life-threatening upper airway ob­
struction. He was intubated, and mechan­
ical ventilation was initiated. Chest X-ray 
revealed bilateral basal consolidations. Af­
ter 3 days, the condition had improved, 
blood gases were normal and the patient 
could be extubated. Stridor immediately 
resumed, however. On fiberoptic bron­
choscopy, the vocal cords appeared to be 
almost completely adducted without ede­
ma or signs of inflammation.
A minitracheostomy was performed and 
treatment with continuous-flow CPAP 
connected to the minitracheostomy was 
started. This resulted in a marked reduc­
tion of the stridor, with adequate ventila­
tion. The patient was successfully weaned 
from this CPAP arrangement without re­
current laryngospasms and was trans­
ferred to the ward after 5 days with 
minitracheostomy in situ. Additional in­
vestigation with body-plethysmography 
breathing showed a marked increase in in­
spiratory resistance, with almost normal 
expiratory resistance, pattern in accor­
dance with extrathoracic, variable airflow 
obstruction, e.g. vocal cord dysfunction. 
Episodes of severe stridor recurred after 2 
weeks. On direct laryncoscopy, the vocal 
cords were still adducted. A permanent 
tracheostomy was performed to avoid fur­
ther ICU admission and interventions.
In Parkinson’s disease, dopamine de­
pletion leads to diminished inhibition of 
the extrapyramidal motor system. This 
may lead to severe laryngospasm. Respira­
tory problems are well known, and aspira* 
tion pneumonia is one of the most com­
mon causes of death among such patients 
[1].
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Dysfunction of the upper airways has 
only recently been recognized in patients 
with Parkinson’s disease [2]. In most 
cases, this leads to impairment of static 
and dynamic pulmonary function. In 
some patients, laryngeal involvement was 
the main reason for airway obstruction 
[2], In our patient, the most likely diag­
nosis is primary laryngospasm associated 
with Parkinson’s disease.
Treatment by minitracheostomy con­
nected to a continous flow CPAP resulted 
in a clinically relevant relief of stridor.
The mechanism of this effect might be 
the slight positive airway pressure of 2-4 
cmH20 in combination with a 4-mm free 
artificial airway. However, the latter can­
not be the only explanation for the clini­
cal relief of stridor, since the stridor in­
creased while the patient was breathing 
through an open minitracheostomy with­
out CPAP connection. Although 
minitracheostomy is most frequently used 
in the treatment of sputum retention, it 
allows an artifical airway to be combined 
with several other arrangements [3, 4],
In conclusion, laryngospasm caused by 
dysfunction of recurrent laryngeal nerves 
may be associated with Parkinson’s dis­
ease. CPAP via minitracheostomy proved 
to be temporarily successful in the man­
agement of this problem. Tracheostomy 
may be inevitable in case of persistent 
relapses.
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Sir: In a recent issue of Intensive Care 
Medicine, Mira et al. [1] presented a 
study concerning the lack of efficiency of 
inhaled nitric oxide in ARDS. They re­
ported a series of six patients with severe 
ARDS who did not respond to NO, three 
of whom responded to a subsequent trial 
of NO. It was suggested that soluble 
gu any late cyclase of pulmonary vascula­
ture smooth muscle could be unresponsive 
to NO.
We used inhaled NO in 30 patients 
with severe ARDS (Pa02/F i02 = 81+8 on 
Fi02 1 PEEP 11 ±1; LIS - 3.45) [2]. NO 
(5 ppm) was administered early (mechani­
cal ventilation for 7±2 days). Twenty- 
eight patients were considered to be NO 
responders (+20% Pa02_/Fi02). We did 
not find any correlation between the im­
provement in arterial oxygenation and the 
decrease in mean pulmonary arterial 
pressure [PAPm = 29 ±3 at TO and 
PAPm «  28 ±2 at Tt hour (NS)]. The 2 
NO non-responders had acute hemorragic 
pulmonary edema with refractory septic 
shock (SAP under 70 mmHg with high 
doses of epinephrine and norepinephrine). 
Owing to hemodynamic instability, PEEP 
levels were low and did not allow for 
alveolar recruitment. In such a situation, 
it is not surprising that an inhaled agent 
might be ineffecient.
According to published studies, 
30-50% of patients are considered to be 
responders to inhaled NO [3, 4], In 
ARDS, pulmonary hypertension is sec­
ondary not only to hypoxic pulmonary 
vasoconstriction, but also to increased 
Va/Q abnormality, atelectasis, loss of vas­
cular bed and small vessel obstruction. 
Given this heterogeneous vascular insult, 
it does not seem surprising that 
pulmonary artery pressure was not 
dramatically changed. Several additional 
factors may interfere with the efficacy of 
NO in patients with severe ARDS: reduc­
tion or loss of the hypoxic pulmonary 
vasoconstriction (pulmonary infection, 
lung trauma, lung hyperinflation) and re­
placement of actively constricted small 
pulmonary vessels by fibrotic and irrever­
sibly narrowed pulmonary vessels [5], The 
last explanation may be of value for the 
patients presented by Mira et aL Indeed,
as a reference center for LFPPV-ECC02R, 
they may have recruited a higher propor­
tion of end-stage ARDS than we did. 
Modifications of pulmonary vasculature 
in late ARDS associated with large areas 
of non-ventilated, non-recruitable paren­
chyma may be responsible for a decreased 
response to inhaled NO.
Finally, the wide variation in respond­
ers to NO inhalation could be related to 
the patient’ pulmonary vascular levels of 
guanylate cyclase, and also to the degree 
of pulmonary parenchyma and vascular 
fibrosis.
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